INTELLIGENCE IN ACTION

Older, Sicker Patients Will Benefit from Real-Time Benefit Tools, So Let’s Not Delay Using Them.

April 15, 2019

Healthcare costs are increasingly prohibitive for too many Americans, and these costs can hit older Americans especially hard. That’s why we applaud the Centers for Medicare & Medicaid Services (CMS) proposed rule on real-time benefit tools (RTBT).

We believe these tools hold the greatest near term promise for making medicine more affordable for patients, particularly for older adults who have multiple medical needs and limited resources. In 2018, prescribers used our tool, Real-Time Prescription Benefit, over 40 million times to view patient-specific prescription price and therapeutic alternative information at the point of care.

The proposed rule, published in the Federal Register late last year, would require Medicare Part D plans to make these tools available to prescribers as soon as possible, with a proposed implementation deadline of January 1, 2020.

Such a deadline will accelerate adoption, meaning vulnerable patients could see real savings much sooner than the implementation date. And when patients can afford medications, they’re more likely to adhere to them.

We know that there are concerns that this timeline is aggressive, but we believe they’re unfounded. The EHRs that have already contracted for Real-Time Prescription Benefit represent 80 percent of U.S. prescribers, and at least three additional vendors offer their own versions of a RTBT. In our comments, we urged CMS to make their decision on timing in favor of patients. Our nation's seniors should benefit from price transparency tools that have developed in the commercial marketplace and are already in widespread use by Part D plans.

To read our comments in their entirety, including more about how tools such as Real-Time Prescription Benefit can accelerate healthcare interoperability, increase price transparency and meet some of the goals of value-based care, please click here.

Related Articles

March 04, 2020

Prescription Price Transparency: Good for Patients, Good for Health Plans

Receiving a diagnosis at a routine doctor’s appointment can be incredibly scary, even for something as treatable as type 2 diabetes. But the right price transparency tools—or lack thereof—can make (or break) that experience for a patient.  Read more...
February 25, 2020

Price Transparency: It’s in the Best Interest of Patients and Providers

“In all my years in health IT this is one of the most exciting and most rapidly adopted clinical decision support tools I’ve ever been associated with,” said Andrew Mellin, MD and vice president of Medical Informatics at Surescripts, referring to Surescripts’ prescription price transparency tool Read more...
February 18, 2020

Patients Are Ready to Talk Dollars with Their Doctors

With more skin in the game than ever before, patients are becoming savvy, engaged and discerning consumers. They know that the name-brand drug with the $300 monthly price tag may not be the only option. They want a healthcare provider who has the information needed to compare and guide them to alternatives that achieve the same or similar outcome. Read more...

INTELLIGENCE IN ACTION, DELIVERED TO YOUR INBOX